Company / Cash & Equivalents
Senti Biosciences Holdings, Inc. Cash & Equivalents History
FY2022-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$16.4M
FY2025
5-year range
$16.4M / $57.6M
FY2022-FY2025
Trend
-66.0%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Declined from $36M to $16M over the past 2 years.
Based on SEC 10-K filings.
$16M in FY2025 with a 3-year CAGR of -34.2%.
Declined from $36M to $16M over the past 2 years.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- -34.2%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- 3-year CAGR of -34.2%, indicating a declining trend.
- In FY2025, cash & equivalents decreased 66.0% year-over-year.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -3.15 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $16.4M | -66.0% |
| FY2024 | $48.3M | +34.4% |
| FY2023 | $35.9M | -37.7% |
| FY2022 | $57.6M | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026